U.S. Markets close in 3 hrs 16 mins

Company Update: AEterna Zentaris Inc. (AEZS) Announces 3Q:17 Highlights and Financial Results

support@smarteranalyst.com (Ben Mahaney)

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) reported financial and operating results for the third quarter ended September 30, 2017.

Third Quarter 2017 Highlights:

  • Macimorelin development progressing toward completion with Prescription Drug User Fee Act date of December 30, 2017;
  • Company prepares for the U.S. Food and Drug Administration (“FDA”) approval and Q1 2018 target commercial launch date;
  • Jeffrey A. Whitnell joins as Interim Chief Financial Officer;
  • Stifel, Nicolaus & Company, Incorporated retained as strategic advisors;
  • Cash on hand of $12.2 million of unrestricted cash and cash equivalents at quarter-end sufficient to take Macrilen™ through approval and no third-party debt;
  • Company adopts disciplined business model focused on cost containment through zero-based budgeting and preserving cash reserves for Macrilen™ product launch.

“We are continuing our laser focus on preparation for the FDA approval of Macrilen™ by December 30, 2017, which will be the only FDA-approved drug for assessing adult growth hormone deficiency in the United States,” said Michael V. Ward, Aeterna Zentaris, Chief Executive Officer. “Our goal is to launch the product in the first quarter of 2018. The Company has reached an important point in its evolution with Jeff Whitnell joining us as the Interim Chief Financial Officer and retention of Stifel Nicolaus during the quarter. We are making progress building out a stronger management team and adopting a disciplined process for strategic review of plans, resources and opportunities. Going forward, we will continue to demonstrate our commitment to ensure that we optimize the use of resources and capital and best position the Company to maximize shareholder value.”

“I am pleased at this time to report that we are almost $2 million dollars ahead in cash reserves of where we thought we would be at this time due to our disciplined new business model that focuses on cost containment realized through zero-based budgeting, said Jeff Whitnell, Interim Chief Financial Officer, Aeterna Zentaris. “These cash reserves position us to take Macrilen™ through approval.”

Third Quarter Financials

All Amounts are in U.S. Dollars

Revenues

Revenues were $241,000 and $745,000 for the three and nine months ended September 30, 2017, as compared to $269,000 and $607,000 for the same periods in 2016. The year-to-date increase is mainly explained by the expanded contract with Armune BioScience, Inc. (APIFINY®), which was effective June 1, 2016 and the amortization of the up-front payment received in connection with one of the out-licensing agreements that we entered into in the third quarter of 2016 for ZoptrexTM.

Research and Development (“R&D”) costs

R&D costs were $4.1 million and $10.2 million for the three and nine months ended September 30, 2017, compared to $4.5 million and $11.9 million for the same periods in 2016. R&D costs decreased for the three-month and nine-month periods ended September 30, 2017. The decrease in our R&D costs is mainly attributable to lower comparative third-party costs partially offset by the recording, in the third quarter of 2017, of a provision in connection with the Restructuring Program.

Third-party costs attributable to Zoptrex™ decreased during the three and nine months ended September 30, 2017, as compared to the same period in 2016, mainly due to the fact that we closed out the study and related activities in the second quarter following the negative ZoptrexTM top-line results on May 1, 2017. The negative costs for the three-month period ended September 30, 2017 are mainly explained by lower close out costs as compared to the accrual made in the second quarter.

Third-party costs attributable to Macrilen™ decreased during the three and nine months ended September 30, 2017, as compared to the same period in 2016. This is mainly due to the fact that we completed the Phase 3 clinical trial at the end of 2016. The costs incurred in 2017 related to the detailed analysis of the top-line results as well as the preparation of the New Drug Application (“NDA”) filing which was submitted on June 30, 2017. The cost incurred in the third quarter of 2017 are explained mainly by the close out costs as well as additional analysis required by the FDA.

General and Administrative (“G&A”) Expenses

G&A expenses were $1.7 million and $5.4 million for both the three and nine-month periods ended September 30, 2017, as compared to $1.6 million and $5.4 million for the same periods in 2016. The G&A expenses were in-line with our expectations.

Selling Expenses

Selling expenses were $1.7 million and $4.6 million for the three and nine months ended September 30, 2017, as compared to $1.8 million and $5.2 million for the same periods in 2016. Selling expenses for the three and nine months ended September 30, 2017 and 2016 represent mainly the costs of our sales force related to co-promotion activities as well as our sales management team. The decrease in selling expenses is explained by the reduction in the number of sales representatives from 20 to 13 since February 2017. In July 2017, we further reduced the number of sales representative to 10 and we reduced our headcount by one sales manager. Following the creation of the Strategic Review Committee, the board of directors of the Company is currently evaluating options to be ready to promote Macrilen™ quickly following the expected approval.

Net Finance (Costs) Income

Net finance (costs) income was $(2.4) million and $3.2 million for the three and nine months ended September 30, 2017, as compared to $1.6 million and $5.1 million, for the same periods in 2016. The decrease in finance income is mainly attributable to the change in fair value recorded in connection with our warrant liability. Such change in fair value results from the periodic "mark-to-market" revaluation, via the application of option pricing models, of outstanding share purchase warrants. The closing price of our common shares, which, on the NASDAQ, fluctuated from $0.84 to $3.65 during the nine-month period ended September 30, 2017, compared to $2.67 to $4.40 during the same period in 2016, also had a direct impact on the change in fair value of warrant liability.

Net Loss

Net loss for the three and nine months ended September 30, 2017 was $9.6 million and $16.3 million (or $0.61 and $1.13 per share), as compared to a net loss of $6.1 million and $16.7 million (or $0.61 and $1.68 per share) for the same periods in 2016. The increase in net loss for the three-month period ended September 30, 2017 is mainly explained by the change in fair value of the warrant liability due to the increase in the share price since June 30, 2017. However, the loss per share during the same period remained stable due to the increase in the weighted average number of shares due to a share issuance done in November 2016 and “at-the-market” issuances done in 2017. The increase in the weighted average number of shares also explains the decrease in the loss per share for the nine-month period.

Liquidity

Cash and cash equivalents were $12.2 million as at September 30, 2017, as compared to $22.0 million as at December 31, 2016. The decrease in cash and cash equivalents as at September 30, 2017, as compared to December 31, 2016, is due to the net cash used in operating activities including variations in components of our working capital. The decrease was partially offset by the net proceeds generated by the issuance of common shares under our various “at-the-market” programs.

Shares of Aeterna Zentaris closed today at $1.90, up $0.01 or 0.53%. AEZS has a 1-year high of $4.25 and a 1-year low of $0.78. The stock's 50-day moving average is $2.05 and its 200-day moving average is $1.65.

On the ratings front, Maxim analyst Jason Kolbert reiterated a Buy rating on AEZS, with a price target of $4.00, in a report issued on August 11. The current price target implies an upside of 111% from current levels. According to TipRanks.com, Kolbert has a yearly average loss of 9.2%, a 33% success rate, and is ranked #4640 out of 4707 analysts.

Æterna Zentaris operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130.

 

More recent articles about AEZS:

  • Sears bankruptcy could make these 5 big companies multi-million-dollar losers
    Finance
    Yahoo Finance

    Sears bankruptcy could make these 5 big companies multi-million-dollar losers

    Signs advertising store closing sales are seen on the doors of a Sears in New Hyde Park, New York, U.S., October 10, 2018. REUTERS/Shannon Stapleton Being an unsecured creditor of Sears (SHLD) right now is not a good place to be. The 125-year old former

  • Brits Are All Making the Same Joke About the New Royal Baby
    News
    Time

    Brits Are All Making the Same Joke About the New Royal Baby

    Meghan Markle, the Duchess of Sussex, is expecting her first child with Prince Harry. The news, announced Monday morning by Kensington Palace, has already been greeted by hundreds of messages of congratulations for the royal couple on social media. The U.K. is set to leave the European Union on March 29, exactly two years after Prime Minister Theresa May started the formal process for doing so by invoking Article 50 of the Lisbon Treaty.

  • Finance
    Bloomberg

    Tesla Skeptic Surprised by How Much He Enjoyed the Model 3

    In a broader note about positive electric-car momentum, Jonas said he observed workers at Tesla’s lone auto plant in Fremont, California, who were “extremely busy cranking out Model 3s” for delivery in the U.S. He also drove the dual-motor performance version of the vehicle, which he sees as having better value-for-performance than the Model S sedan. “Frankly, our enjoyment of the high-spec version of the Model 3 took us by surprise,” Jonas said, adding that it’s “hard to say how much this matters.

  • Better Marijuana Stock: Aurora Cannabis vs. Auxly Cannabis Group
    Business
    Motley Fool

    Better Marijuana Stock: Aurora Cannabis vs. Auxly Cannabis Group

    One is market cap: Aurora's market cap is nearly 18 times bigger than Auxly's. Then there's stock performance. Here's how Aurora Cannabis and Auxly Cannabis Group stack up against each other in the areas that do matter.

  • Bank of America Earnings: Better Margins, Strong Asset Quality, and an All-Around Good Quarter
    Business
    Motley Fool

    Bank of America Earnings: Better Margins, Strong Asset Quality, and an All-Around Good Quarter

    Bank of America (NYSE: BAC) is the last of the "big four" U.S. banks to report its third-quarter earnings. Not only did Bank of America beat expectations on both the top and bottom lines, but the business looks pretty solid all around. First, looking at the top and bottom lines, Bank of America did quite well in the third quarter.

  • This Is the Average American's Salary. How Does Yours Compare?
    Business
    Motley Fool

    This Is the Average American's Salary. How Does Yours Compare?

    In an age of oversharing, many of us are remarkably tight-lipped when it comes to talking salary. But in reality, knowing where you stand can help you determine whether you're in a good place or whether you should be taking steps to boost your earnings

  • Caterpillar Announces Quarterly Cash Dividend—Makes No Changes
    Business
    Market Realist

    Caterpillar Announces Quarterly Cash Dividend—Makes No Changes

    On October 10, Caterpillar (CAT) declared its latest quarterly dividend. Caterpillar has been paying dividends since 1933. Caterpillar has also announced the key dates for its third-quarter dividend payment.

  • Ark Invest CEO: Tesla 'is a replay of Apple'
    Finance
    Yahoo Finance

    Ark Invest CEO: Tesla 'is a replay of Apple'

    Tesla (TSLA) and Apple (APPL) have at least one thing in common – and it’s a big factor leading one analyst to project a price target of $4,000 for the electric vehicle manufacturer. It comes down to the chips, ARK Invest CEO and CIO Cathie Wood said in an interview with Yahoo Finance on Friday. Tesla CEO Elon Musk confirmed in August that the company would be making its own computer chips for automated driving, pivoting away from hardware produced by chipmaker Nvidia (NVDA).

  • Ford Escape sales are down — here’s how it compares with other small SUVs
    Business
    American City Business Journals

    Ford Escape sales are down — here’s how it compares with other small SUVs

    Sales of the Ford Escape aren't what they used to be. The Escape, made at the Louisville Assembly Plant, saw sales decline by 20 percent in September 2018, compared with the same month last year. Ford and its Lincoln Motor Co. subsidiary have been successful in increasing sales of larger SUVs, such as the Navigator and Expedition this year.

  • Sears files for bankruptcy
    Business
    Yahoo Finance Video

    Sears files for bankruptcy

    Sears has officially for bankruptcy as CEO Eddie Lampert tries to turn the struggling retailer around. Yahoo Finance’s Alexis Christoforous, Brian Sozzi, Melody Hahm and Ethan Wolff-Mann discuss.

  • 2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better
    Business
    Motley Fool

    2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better

    During a tough week for the overall market, pharmaceutical stocks across the board fell a few notches despite a lack of significant news for the industry itself. Over the past five years, Pfizer has been able to raise its dividend 42% despite declining sales for aging blockbusters that lost patent protection and a sterile injectibles business that suffered major product shortages after it was acquired. Now that the worst is over, a strong product lineup and bulging pipeline could allow America's largest pharmaceutical company to direct a ton of cash toward its shareholders.

  • Tesla Model 3 hits major milestone
    TSLA
    Fox Business Videos

    Tesla Model 3 hits major milestone

    FBN's Cheryl Casone on Tesla reaching a milestone of 100,000 Model 3 vehicles and Tesla CEO Elon Musk filing the paperwork to create a Tesla brand tequila called 'Teslaquila.'

  • Southwest balks at American's new idea for Cuba routes
    Business
    American City Business Journals

    Southwest balks at American's new idea for Cuba routes

    Southwest ripped American's proposed rule change that would alter how U.S. airlines handle their routes to Cuba, calling the idea "unprecedented" in an Oct. 10 regulatory filing. Only 20 daily routes to Havana were allocated to U.S. airlines. Both American Airlines Group, Inc. (NASDAQ: AAL) and Southwest Airlines Co. (NYSE: LUV) were granted routes.

  • NVIDIA Soars in AI Market With New Platform & Partnerships
    Finance
    Zacks

    NVIDIA Soars in AI Market With New Platform & Partnerships

    NVIDIA Corporation’s NVDA efforts in artificial intelligence (AI) and machine learning in various fields are gathering momentum, thanks to its initiatives and adoption of its technologies by key companies.The past week has been quite eventful for NVIDIA

  • Business
    Benzinga

    Insider Buys Of The Week: Conagra, Salesforce, Thor

    Conventional wisdom says insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. While the board chair and other Salesforce.com, inc. (NYSE: CRM) executives have been selling throughout October, one director stepped up to the buy window this past week. The stock ended Friday at $146.74, down more than 4 percent for the week, and above the director's purchase price range.

  • Microsoft Earnings: Mark Your Calendar
    Business
    Motley Fool

    Microsoft Earnings: Mark Your Calendar

    Software giant Microsoft (NASDAQ: MSFT) has continued to impress investors in 2018 amid its ongoing progress becoming a more cloud-centric company. Microsoft reports its first-quarter earnings for fiscal 2019 on October 24. Ahead of Microsoft's earnings release, here's an overview of some of the key areas investors will want to watch. Core to Microsoft's momentum recently is the company's rapidly growing commercial-cloud revenue.

  • Will Procter & Gamble Start Its New Fiscal Year on the Right Foot?
    Business
    Motley Fool

    Will Procter & Gamble Start Its New Fiscal Year on the Right Foot?

    Procter & Gamble (NYSE: PG) is less than a week away from its first earnings report of a new fiscal year, and shareholders are hoping for better results than what it delivered the previous two quarters, which were marked by sluggish sales growth that missed management's targets. P&G has been working to end a stubborn period of modest market share losses for several of its core franchises. Organic sales growth, which measures core revenue growth by factoring out exchange rate shifts and brand acquisitions, slowed to a 1% rate over the prior 12 months from 2% in fiscal 2017.

  • Better Marijuana Stock: Canopy Growth Corporation vs. Aphria Inc.
    Business
    Motley Fool

    Better Marijuana Stock: Canopy Growth Corporation vs. Aphria Inc.

    Recreational marijuana sales begin on Oct. 17 in Canada, and investors convinced the program will be a hit have pushed shares of Canopy Growth Corporation (NYSE: CGC) and Aphria Inc. (NASDAQOTH: APHQF) up by 60% or better over the past few months. In just two short years, Canopy Growth Corporation's market cap has exploded from just $476 million two years ago to $10.1 billion at recent prices, and it looks like there could be more fireworks ahead. Canopy Growth has secured contracts that will require it to provide at least 67,000 kilograms of cannabis annually to Canadian provinces and territories.

  • Warren Buffett predicted the fall of Eddie Lampert and Sears over 10 years ago (SHLD, BRK.A, BRK.B)
    Finance
    Business Insider

    Warren Buffett predicted the fall of Eddie Lampert and Sears over 10 years ago (SHLD, BRK.A, BRK.B)

    Sears filed for Chapter 11 bankruptcy early Monday, the culmination of a downward spiral. CEO Eddie Lampert, once called the "next Warren Buffett," will also step down. Incidentally, Buffett predicted the retailer's and Lampert's downfall in 2005.

  • 3 Top Small-Cap Stocks to Buy in October
    Business
    Motley Fool

    3 Top Small-Cap Stocks to Buy in October

    This fall, think small. To be more specific, think about buying small-cap stocks. Why? Small-cap stocks have the most growth potential. It's hard for a stock with a market cap of $500 billion to double. But it's a different story for stocks with market

  • Intel on Track to Report Record Earnings in Fiscal 2018
    Business
    Market Realist

    Intel on Track to Report Record Earnings in Fiscal 2018

    The world is moving toward the data economy, and Intel (INTC) is at the center of this trend. Intel is investing in the four fast-growing markets of 5G, AI, IoT, and autonomous vehicles. Intel has partnered with several Chinese companies.

  • What Investors Should Know about AT&T’s Growth Prospects
    Business
    Market Realist

    What Investors Should Know about AT&T’s Growth Prospects

    What Investors Should Know about AT&T’s Growth Prospects AT&T’s earnings in Q3 2018 AT&T (T), the second-largest wireless service provider in the United States, is looking to showcase its strength as it nears its third-quarter earnings release. The company

  • 2 Hot Marijuana Stocks Listing Soon on U.S. Exchanges -- Are They Buys?
    Business
    Motley Fool

    2 Hot Marijuana Stocks Listing Soon on U.S. Exchanges -- Are They Buys?

    Two marijuana stocks that are currently listed on Canadian stock exchanges soon plan also to list on U.S. stock exchanges. Aurora Cannabis (NASDAQOTH: ACBFF) (TSX: ACB) expects to trade on the New York Stock Exchange (NYSE) by the end of October and Aleafia Health (NASDAQOTH: ALEAF) should soon trade on the Nasdaq stock exchange. Are these hot marijuana stocks that are coming soon to U.S. stock exchanges smart picks to buy now?

  • Why I’m Not Worried About Being Behind on Retirement Savings
    Business
    GoBankingRates

    Why I’m Not Worried About Being Behind on Retirement Savings

    This is why I find it funny that we spend most of our lives “retirement planning” or planning for our deaths. Don’t get me wrong, I’m not shouting in the face of retirement planning or being prepared. Although I’ve gotten my life back on track since then, I’m still not worried about being behind on retirement savings, the magical “$1 million saved” for retirement number or all the “what ifs.” Why?

  • It’s Official -- These 5 Social Security Changes Are Coming for 2019
    Business
    Motley Fool

    It’s Official -- These 5 Social Security Changes Are Coming for 2019

    For workers, Social Security's maximum taxable earnings are increasing, and more income will be required to earn a Social Security "credit." Beneficiaries who claimed Social Security early and still work will be happy to learn they'll be able to earn more without a benefit reduction in 2019, and for high earners, the maximum possible Social Security benefit is also on the rise. With all of that in mind, here are the recently released details of these five 2019 Social Security changes. As I mentioned, Social Security beneficiaries are getting a 2.8% COLA starting with their January 2019 benefit payment.